Results 191 to 200 of about 7,117 (221)

Integrating Quality by Design and Green Chemistry for Sustainable Drug Development: Acalabrutinib Stability Study

Chromatographia
Anuj N. Nahata, Himanshu Pawar, Mitali A. Patel   +2 more
semanticscholar   +1 more source

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

Lancet Haematology,the, 2020
Simon A Rule, Olivier Tournilhac, Francesco Forconi   +2 more
exaly  

Acalabrutinib (Zweitlinie)

2021
Wörmann, Bernhard, Wendtner, Clemens, Stilgenbauer, Stephan, Schetelig, Johannes, Eichhorst, Barbara, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +6 more
openaire   +1 more source

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Journal of Clinical Oncology, 2020
Paolo Ghia, Javier De La Serna, Wojciech Jurczak   +2 more
exaly  

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Lancet, The, 2018
Michael Wang, Simon A Rule, Pier Luigi Zinzani   +2 more
exaly  

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Lancet, The, 2020
Jeff P Sharman, Miklos Egyed, Wojciech Jurczak   +2 more
exaly  

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2016
John C Byrd, Bonnie K Harrington, Susan M O'brien   +2 more
exaly  

Acalabrutinib

Reactions Weekly, 2019
openaire   +1 more source

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Cancer, 2020
Tian Zhang, Mhs, Michael R Harrison, Peter H O'donnell   +2 more
exaly  

EFFICACY OF RITUXIMAB‐BENDAMUSTINE WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH UNTREATED, HIGH‐RISK MANTLE CELL LYMPHOMA: AN ANALYSIS OF THE PHASE 3 ECHO TRIAL

Hematological Oncology
M. Dreyling, P. Zinzani, M. Pavlovsky, K. Bouabdallah, M. Bastos-Oreiro, E. John, V. Otero, A. Goy   +7 more
semanticscholar   +1 more source